Antibody-Drug Conjugates in PTCL
|Author(s)/Faculty: Owen A. O'Connor, MD, PhD; Lorenz Trümper, MD|
|Release Date: 11/11/2019||Expiration Date: 11/10/2020|
|Credit Type: CME||Number of Credits: 0.25|
|Content Type: Podcast||Provider: |
|Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast expert clinicians will discuss antibody-drug conjugates in PTCL.